Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNA2 | P20248 | 1/20 | 0.40 |
| ▸ | CDK2 | P24941 | 1/20 | 0.40 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.40 |
| ▸ | ABL1 | P00519 | 2/20 | 0.39 |
| ▸ | GFER | P55789 | 1/20 | 0.38 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.37 |
| ▸ | BCHE | P06276 | 1/20 | 0.37 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.37 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.37 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.37 |
| ▸ | USP2 | O75604 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | THRB | P10828 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | THPO | P40225 | 1/20 | 0.36 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.36 |
| ▸ | P2RX2 | Q9UBL9 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16992336 | 1.00 | CCNA2 (0.40) | CCNA2CDK2CCNA1ABL1GFER | |
| SCHEMBL609915 | 0.81 | NOTUM (0.42) | CCNA2CDK2CCNA1USP2KDM4E | |
| SCHEMBL4636834 | 0.80 | GAA (0.46) | CCNA2CDK2CCNA1ABL1MEN1 | |
| SCHEMBL16480393 | 0.79 | TDP1 (0.47) | CCNA2CDK2CCNA1ABL1GFER | |
| SCHEMBL22658820 | 0.79 | SLC6A2 (0.46) | CCNA2CDK2CCNA1ABL1TSHR | |
| SCHEMBL25416662 | 0.79 | ALDH1A1 (0.42) | CCNA2CDK2CCNA1ABL1GFER | |
| SCHEMBL30912518 | 0.79 | ALDH1A1 (0.42) | CCNA2CDK2CCNA1ABL1GFER | |
| SCHEMBL11112763 | 0.79 | ESR1 (0.49) | CCNA2CDK2CCNA1ABL1HRH3 | |
| SCHEMBL10131414 | 0.79 | CYP3A4 (0.41) | CCNA2CDK2CCNA1ABL1HRH3 | |
| SCHEMBL30912507 | 0.79 | ALDH1A1 (0.42) | CCNA2CDK2CCNA1ABL1GFER |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107949384-B | Muscarinic agonists | 奈克斯拉制药英国有限公司 | 2025-02-28 | — | — | CN | disclosed |
| US-11324738-B2 | Muscarinic agonists | HEPTARES THERAPEUTICS LIMITED (GB) | 2022-05-10 | — | — | US | disclosed |
| US-11324738-B2 | Muscarinic agonists | HEPTARES THERAPEUTICS LIMITED (GB) | 2022-05-10 | — | — | US | disclosed |
| EP-3331528-B1 | MUSCARINIC AGONISTS | HEPTARES THERAPEUTICS LTD (GB) | 2021-09-29 | — | — | EP | disclosed |
| EP-3331528-B1 | MUSCARINIC AGONISTS | HEPTARES THERAPEUTICS LTD (GB) | 2021-09-29 | — | — | EP | disclosed |
| US-20200129496-A1 | MUSCARINIC AGONISTS | NXERA PHARMA UK LIMITED (GB) | 2020-04-30 | — | — | US | disclosed |
| US-20200129496-A1 | MUSCARINIC AGONISTS | NXERA PHARMA UK LIMITED (GB) | 2020-04-30 | — | — | US | disclosed |
| US-10548884-B2 | Muscarinic agonists | HEPTARES THERAPEUTICS LIMITED (GB) | 2020-02-04 | — | — | US | disclosed |
| EP-3331528-A1 | MUSCARINIC AGONISTS | Heptares Therapeutics Limited (GB) | 2018-06-13 | — | — | EP | disclosed |
| WO-2017021728-A9 | MUSCARINIC AGONISTS | HEPTARES THERAPEUTICS LIMTED (GB) | 2017-04-27 | — | — | WO | disclosed |
| WO-2017021728-A9 | MUSCARINIC AGONISTS | HEPTARES THERAPEUTICS LIMTED (GB) | 2017-04-27 | — | — | WO | disclosed |
| WO-2017021728-A1 | MUSCARINIC AGONISTS | HEPTARES THERAPEUTICS LIMTED (GB) | 2017-02-09 | — | — | WO | disclosed |
| WO-2017021728-A1 | MUSCARINIC AGONISTS | HEPTARES THERAPEUTICS LIMTED (GB) | 2017-02-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10548884-B2 | Muscarinic agonists | CHRM1, CHRM2, CHRM4 | CCNA2 2734/4885CDK2 2733/4885CCNA1 1624/4885 |
| US-20200129496-A1 | MUSCARINIC AGONISTS | CHRM1, CHRM2, CHRM4 | CCNA2 2807/4885CDK2 2890/4885CCNA1 1550/4885 |
| US-11324738-B2 | Muscarinic agonists | CHRM1, CHRM2, CHRM4 | CCNA2 2807/4885CDK2 2890/4885CCNA1 1550/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.